Telomir Pharmaceuticals (TELO) Competitors

Telomir Pharmaceuticals logo
$4.27 +0.02 (+0.47%)
Closing price 04:00 PM Eastern
Extended Trading
$4.44 +0.18 (+4.10%)
As of 05:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TELO vs. XERS, PGEN, HUMA, TECX, TKNO, MLYS, SNDL, TRDA, KMDA, and RNAC

Should you be buying Telomir Pharmaceuticals stock or one of its competitors? The main competitors of Telomir Pharmaceuticals include Xeris Biopharma (XERS), Precigen (PGEN), Humacyte (HUMA), Tectonic Therapeutic (TECX), Alpha Teknova (TKNO), Mineralys Therapeutics (MLYS), SNDL (SNDL), Entrada Therapeutics (TRDA), Kamada (KMDA), and Cartesian Therapeutics (RNAC). These companies are all part of the "pharmaceutical products" industry.

Telomir Pharmaceuticals vs.

Xeris Biopharma (NASDAQ:XERS) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Telomir Pharmaceuticals has lower revenue, but higher earnings than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xeris Biopharma$163.91M3.27-$62.26M-$0.45-8.00
Telomir PharmaceuticalsN/AN/A-$13.07M-$0.58-7.36

In the previous week, Telomir Pharmaceuticals had 5 more articles in the media than Xeris Biopharma. MarketBeat recorded 5 mentions for Telomir Pharmaceuticals and 0 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.00 beat Telomir Pharmaceuticals' score of -0.42 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company Overall Sentiment
Xeris Biopharma Neutral
Telomir Pharmaceuticals Neutral

Xeris Biopharma received 144 more outperform votes than Telomir Pharmaceuticals when rated by MarketBeat users.

CompanyUnderperformOutperform
Xeris BiopharmaOutperform Votes
144
69.90%
Underperform Votes
62
30.10%
Telomir PharmaceuticalsN/AN/A

Xeris Biopharma presently has a consensus price target of $5.15, indicating a potential upside of 43.06%. Given Xeris Biopharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Xeris Biopharma is more favorable than Telomir Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xeris Biopharma
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
Telomir Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

42.8% of Xeris Biopharma shares are owned by institutional investors. 4.6% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Telomir Pharmaceuticals has a net margin of 0.00% compared to Xeris Biopharma's net margin of -33.69%. Xeris Biopharma's return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Xeris Biopharma-33.69% N/A -17.38%
Telomir Pharmaceuticals N/A -1,170.58%-832.67%

Summary

Xeris Biopharma beats Telomir Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Get Telomir Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TELO vs. The Competition

MetricTelomir PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$127.08M$6.93B$5.81B$9.18B
Dividend YieldN/A2.90%5.29%4.00%
P/E Ratio-7.369.8526.0719.43
Price / SalesN/A289.06460.2377.15
Price / CashN/A75.4646.0938.87
Price / Book213.505.577.415.07
Net Income-$13.07M$123.72M$3.19B$222.90M
7 Day Performance-5.53%-2.08%-0.23%0.37%
1 Month Performance-5.11%1.11%6.21%5.51%
1 Year Performance-39.09%5.75%26.11%23.18%

Telomir Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TELO
Telomir Pharmaceuticals
N/A$4.27
+0.5%
N/A-32.0%$127.08MN/A-7.361
XERS
Xeris Biopharma
3.2524 of 5 stars
$3.57
+0.6%
$5.15
+44.3%
+21.4%$529.24M$187.36M-7.93290
PGEN
Precigen
4.0238 of 5 stars
$1.78
+4.7%
$7.00
+293.3%
+33.6%$521.31M$6.22M-3.24190
HUMA
Humacyte
3.2093 of 5 stars
$4.13
-0.5%
$13.71
+232.1%
+2.3%$519.80M$1.57M-3.08150Short Interest ↓
TECX
Tectonic Therapeutic
3.0221 of 5 stars
$34.77
-4.6%
$80.50
+131.5%
N/A$512.86MN/A-5.90120Short Interest ↑
Gap Up
TKNO
Alpha Teknova
0.8169 of 5 stars
$9.17
+1.8%
$8.50
-7.3%
+135.4%$488.85M$36.68M-12.39240Analyst Forecast
Positive News
Gap Up
MLYS
Mineralys Therapeutics
3.0921 of 5 stars
$9.51
-3.1%
$30.00
+215.5%
-27.8%$488.23MN/A-2.9128Earnings Report
Analyst Forecast
News Coverage
Gap Down
SNDL
SNDL
3.9889 of 5 stars
$1.85
-0.5%
$3.25
+75.7%
+31.9%$486.14M$673.33M-5.972,516
TRDA
Entrada Therapeutics
2.7396 of 5 stars
$12.86
-0.6%
$25.67
+99.6%
-16.3%$481.22M$129.01M8.09110
KMDA
Kamada
4.4569 of 5 stars
$8.33
+8.3%
$14.50
+74.1%
+34.6%$478.81M$142.52M29.75360Short Interest ↓
News Coverage
Positive News
Gap Up
High Trading Volume
RNAC
Cartesian Therapeutics
2.5974 of 5 stars
$18.51
+0.8%
$42.86
+131.5%
-9.9%$470.43M$47.94M-0.3564Analyst Revision

Related Companies and Tools


This page (NASDAQ:TELO) was last updated on 2/13/2025 by MarketBeat.com Staff
From Our Partners